Treatment of endometriosis with goserelin depot, a long-acting gonadotropin-releasing hormone agonist analog: Endocrine and clinical results

P. L. Venturini, V. Fasce, S. Costantini, P. Anserini, S. Cucuccio, L. De Cecco

Research output: Contribution to journalArticlepeer-review

Abstract

Thirty-two patients with laparoscopic diagnosis of endometriosis were treated for 6 months with the gonadotropin-releasing hormone agonist goserelin depot. Hormonal and clinical evaluations were conducted during treatment and for a 6-month follow-up period. Serum 17β-estradiol levels were sharply suppressed. Luteinizing hormone was also decreased, whereas follicle-stimulating hormone, after an initial fall, gradually rose to pretreatment levels. Ovarian androgenic production was less inhibited, total testosterone being the only significantly suppressed hormone. There was a marked improvement of signs and symptoms of endometriosis and a 47.3% reduction of laparoscopic score. The results of this study suggest that goserelin depot provides a very good suppression of ovarian estrogen production and is highly effective in decreasing the symptoms of endometriosis with an acceptable compliance by the patient.

Original languageEnglish
Pages (from-to)1021-1027
Number of pages7
JournalFertility and Sterility
Volume54
Issue number6
Publication statusPublished - 1990

ASJC Scopus subject areas

  • Obstetrics and Gynaecology

Fingerprint

Dive into the research topics of 'Treatment of endometriosis with goserelin depot, a long-acting gonadotropin-releasing hormone agonist analog: Endocrine and clinical results'. Together they form a unique fingerprint.

Cite this